Shared on 24 Aug 25

Fair value Decreased 6.60%

Valneva's substantial improvement in net profit margin and sharp reduction in future P/E have led to a notable upward revision in the consensus analyst price target from €6.97 to €7.48. What's in the News Health Canada granted marketing authorization for IXCHIQ, Valneva’s single-dose chikungunya vaccine, for individuals aged 12 years and older, supported by robust antibody persistence and safety data.

Read more

0 votesShare

Shared on 01 Aug 25

Fair value Increased 12%

Valneva's consensus analyst price target has increased to €6.95, primarily driven by a sharp rise in future P/E despite a decline in net profit margin. What's in the News Valneva entered a development and manufacturing agreement with AGC Biologics for Phase 2 supply of its four-valent Shigella vaccine, with recent Phase 2 studies in infants and human challenge trials planned.

Read more

0 votesShare